facebook button D9106C00001: Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable Non-small Cell Lung Cancer
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

D9106C00001: Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable Non-small Cell Lung Cancer

Sponsor: AstraZeneca

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of major pathological response.

For more information please contact the clinical research department: 631-675-5075